Trials / Completed
CompletedNCT06345183
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Real-World Treatment Patterns and Outcomes of Advanced Renal Cell Carcinoma (aRCC) Patients Receiving Nivolumab+Ipilimumab or Pembrolizumab+Lenvatinib in U.S. Oncology Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 327 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Nivolumab + Ipilimumab combination therapy | As per product label |
| COMBINATION_PRODUCT | Pembrolizumab + Lenvatinib combination therapy | As per product label |
Timeline
- Start date
- 2024-02-19
- Primary completion
- 2024-04-04
- Completion
- 2024-04-04
- First posted
- 2024-04-03
- Last updated
- 2025-11-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06345183. Inclusion in this directory is not an endorsement.